We thus concluded that the combined inhibition of ALK and RAF1 triggered enhanced autophagy, through relieving inhibition of the ULK1 protein, and may represent a more effective therapy, in comparison with single crizotinib treatment, for ALK+ ALCL lymphomas (Figure 1). This evidence concerns the gene ALK and lymphoma.